COPENHAGEN – Danish drugmaker Novo Nordisk said on Monday it has cut U.S. consumer prices for its weight-loss drug Wegovy and diabetes treatment Ozempic, expanding efforts by the company and the Trump administration to improve access to the blockbuster medicines.
The company is reducing the monthly cost for most cash-paying patients to $349 from $499. However, the highest dose of Ozempic will remain at $499.
Novo Nordisk also launched a temporary introductory offer, allowing new cash-paying patients to access the two lowest doses of both Wegovy and Ozempic for $199 per month for the first two months. After that, patients will pay the new standard price. The offer ends on March 31.
The moves come days after President Donald Trump announced agreements with Novo Nordisk and rival Eli Lilly to lower drug costs and increase availability. The deals involve reducing government prices, introducing Medicare coverage for obesity drugs for some patients, and offering discounted medicines on a new government website, TrumpRx, launching in January.
“Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay,” said Dave Moore, Novo Nordisk’s head of U.S. operations, in a statement.
The Trump administration said starting doses of drugs like Wegovy and Eli Lilly’s Zepbound will be $350 per month on TrumpRx, eventually falling to $245 over two years.
Following the announcement of the government deals, Eli Lilly said it would cut prices by $50 on its direct-to-consumer platform, LillyDirect. Zepbound’s lowest dose will now be $299 per month.
Novo Nordisk’s new cash-pay offers are available through its websites, its NovoCare pharmacy, and partners including Costco, WeightWatchers, and various telehealth providers.